H.R. 9418 · 119th Congress · Health

Access to Innovative Treatments Act of 2026

In committee661 words Introduced Jun 24, 2026 · Latest action Jun 24, 2026

How far it has goneStage 2 of 6
  1. IntroducedJun 24, 2026 Done
  2. CommitteeReferred to 2 committees Current stage
  3. House floorNot yet Not reached yet
  4. Senate floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so.

Specifically, the CMS must review within 30 days any denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration (FDA). The bill's requirements do not apply if the CMS already conducted such a review within a two-year period.

The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.

Congressional Research Service · summary of “Introduced in House” version · Jun 24, 2026

Who lobbies on it

2 organizations, more than 77% of House bills · 3 filings · Q2 2026–Q3 2026

See which of this bill’s sponsors and cosponsors got money from the lobbying organizations’ PACs → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Alzheimer's Association 2 of 2 quarters
    “…and Retention Support (CAREERS) Act of 2023 (S. 10 118th Congress) Access to Innovative Treatments Act of 2026 (H.R. 9418) Mandating Exclusive Review of Individual Treatments (MERIT) Act of 2023 (H.R. 133 118th Congress) Elder Justice Reauthorization and Modernization Act of 2023 (S. 1198/H.R. 2718 118th Congress)…”

    $3.7M lobbying spend in 2026 to date, all issuesQ3 2026 filing

  2. Biotechnology Innovation Organization 1 of 2 quarters
    “…H.R.9418: Access to Innovative Treatments Act of 2026 ---S.526: Pharmacy Benefit Manager Transparency Act ---S.1097: Interagency Patent Coordination and Improvement Act ---S.1954: Biosimilar Red Tape Elimination Act ---S.3014: Ensuring Timely Access to Generics ---CMMI Authority ---Ensuring Access to Generic…”

    $6.5M lobbying spend in 2026 to date, all issuesQ3 2026 filing

Organizations that named H.R. 9418 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Jun 24, 2026Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  2. Jun 24, 2026Introduced in House